AR026024A1 - Compuestos inhibidores sglt2 de glucosidos de c-arilo y metodo, las composiciones faramceuticas que los contienen y los intermediarios de sintesis dedichos compuestos - Google Patents

Compuestos inhibidores sglt2 de glucosidos de c-arilo y metodo, las composiciones faramceuticas que los contienen y los intermediarios de sintesis dedichos compuestos

Info

Publication number
AR026024A1
AR026024A1 ARP000105373A ARP000105373A AR026024A1 AR 026024 A1 AR026024 A1 AR 026024A1 AR P000105373 A ARP000105373 A AR P000105373A AR P000105373 A ARP000105373 A AR P000105373A AR 026024 A1 AR026024 A1 AR 026024A1
Authority
AR
Argentina
Prior art keywords
compounds
aryl
heterocycle
pharmaceutical compositions
compositions containing
Prior art date
Application number
ARP000105373A
Other languages
English (en)
Spanish (es)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26855382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR026024(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR026024A1 publication Critical patent/AR026024A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ARP000105373A 1999-10-12 2000-10-12 Compuestos inhibidores sglt2 de glucosidos de c-arilo y metodo, las composiciones faramceuticas que los contienen y los intermediarios de sintesis dedichos compuestos AR026024A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15877399P 1999-10-12 1999-10-12
US19461500P 2000-04-05 2000-04-05

Publications (1)

Publication Number Publication Date
AR026024A1 true AR026024A1 (es) 2002-12-26

Family

ID=26855382

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105373A AR026024A1 (es) 1999-10-12 2000-10-12 Compuestos inhibidores sglt2 de glucosidos de c-arilo y metodo, las composiciones faramceuticas que los contienen y los intermediarios de sintesis dedichos compuestos

Country Status (32)

Country Link
US (1) US6414126B1 (forum.php)
EP (1) EP1224195B1 (forum.php)
JP (1) JP4365554B2 (forum.php)
KR (1) KR100728085B1 (forum.php)
CN (1) CN1284793C (forum.php)
AR (1) AR026024A1 (forum.php)
AT (1) ATE295848T1 (forum.php)
AU (1) AU781009B2 (forum.php)
BR (2) BRPI0014722B8 (forum.php)
CA (1) CA2388818C (forum.php)
CO (1) CO5251414A1 (forum.php)
CZ (1) CZ304522B6 (forum.php)
DE (1) DE60020259T2 (forum.php)
EG (1) EG24515A (forum.php)
ES (1) ES2240179T3 (forum.php)
HK (1) HK1044541B (forum.php)
HU (2) HU229446B1 (forum.php)
IL (2) IL148806A0 (forum.php)
IN (1) IN2007MU00019A (forum.php)
MX (1) MX237254B (forum.php)
MY (1) MY125405A (forum.php)
NO (2) NO323698B1 (forum.php)
NZ (1) NZ518029A (forum.php)
PE (1) PE20011000A1 (forum.php)
PH (1) PH12000002657B1 (forum.php)
PL (1) PL204358B1 (forum.php)
PT (1) PT1224195E (forum.php)
RU (1) RU2262507C2 (forum.php)
TR (1) TR200200986T2 (forum.php)
TW (1) TWI254714B (forum.php)
UY (1) UY26391A1 (forum.php)
WO (1) WO2001027128A1 (forum.php)

Families Citing this family (321)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) * 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
RU2002120498A (ru) * 1999-12-28 2004-04-10 Адзиномото Ко., Инк. (Jp) Противодиабетический препарат для перорального введения
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
JP2003531590A (ja) 2000-04-12 2003-10-28 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
FR2809310B1 (fr) * 2000-05-26 2004-02-13 Centre Nat Rech Scient Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
BR0115055A (pt) 2000-10-30 2003-12-30 Ortho Mcneil Pharm Inc Terapia de combinação compreendendo agentes anticonvulsantes e antidiabéticos
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US7067148B2 (en) * 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
EP1385856B1 (en) * 2001-04-11 2006-02-22 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
WO2003011880A1 (fr) * 2001-07-31 2003-02-13 Kissei Pharmaceutical Co., Ltd. Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030175337A1 (en) * 2001-10-29 2003-09-18 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
US6984645B2 (en) * 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
DK1463751T3 (da) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albuminfusionsproteiner.
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
CA2481371A1 (en) * 2002-03-11 2003-09-18 Peter Zahradka Use of ppar alpha agonists for the treatment of vascular and renal diseases
US20050215489A1 (en) * 2002-03-14 2005-09-29 Bayer Pharmaceuticals Corporation Methods of treating diabetes using pde 11a inhibitors
JP4424203B2 (ja) * 2002-04-26 2010-03-03 味の素株式会社 糖尿病予防・治療剤
US7956041B2 (en) 2002-04-26 2011-06-07 Ajinomoto Co., Inc. Prophylactic and therapeutic agent of diabetes mellitus
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
JP4530855B2 (ja) 2002-10-04 2010-08-25 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
BR0317929A (pt) * 2003-01-03 2006-04-11 Bristol Myers Squibb Co métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
ES2363941T3 (es) * 2003-03-14 2011-08-19 Astellas Pharma Inc. Derivados de c-glucósido para el tratamiento de diabetes.
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
CA2524134C (en) * 2003-04-28 2017-07-04 Sankyo Company Limited Adiponectin production enhancer
AU2004233691B2 (en) * 2003-04-28 2007-09-20 Sankyo Company, Limited Sugar intake-ability enhancer
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
EA009768B1 (ru) * 2003-08-01 2008-04-28 Янссен Фармацевтика Нв Замещенные конденсированные гетероциклические с-гликозиды
EP1680414A4 (en) 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED INDAZOLE-O-GLUCOSIDE
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
US7094764B2 (en) 2003-08-01 2006-08-22 Janssen Pharmaceutica N.V. Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides
CA2549025A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US8258105B2 (en) * 2003-10-07 2012-09-04 Isis Pharmaceuticals, Inc. Antisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
SI1689757T1 (sl) 2003-11-12 2015-01-30 Sino-Med International Alliance, Inc. Heterociklične spojine boronske kisline
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1581246B1 (en) * 2003-12-17 2013-01-16 Amylin Pharmaceuticals, LLC Compositions for the treatment and prevention of nephropathy
JP2006514649A (ja) * 2003-12-17 2006-05-11 アミリン・ファーマシューティカルズ，インコーポレイテッド 腎症の治療および予防のための組成物
US7371732B2 (en) * 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
CN1934122B (zh) * 2004-03-04 2010-08-04 橘生药品工业株式会社 稠合杂环衍生物、包含该稠合杂环衍生物的药物组合物、及其药学应用
ZA200608028B (en) * 2004-03-04 2009-03-25 Kissei Pharmaceutical Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
AU2005225511C1 (en) 2004-03-16 2023-04-13 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
WO2005095373A1 (ja) * 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. ナフタレン誘導体、それを含有する医薬組成物およびその医薬用途
JPWO2005095372A1 (ja) * 2004-03-31 2008-02-21 キッセイ薬品工業株式会社 ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
EP1731524A4 (en) * 2004-03-31 2009-05-20 Kissei Pharmaceutical PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2006006496A1 (ja) * 2004-07-08 2006-01-19 Astellas Pharma Inc. アズレン誘導体の製造方法及びその合成中間体
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
ES2581331T3 (es) 2004-07-21 2016-09-05 Kissei Pharmaceutical Co., Ltd. Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
JP2008508213A (ja) * 2004-07-27 2008-03-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄ−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
WO2006018150A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
MX2007003785A (es) * 2004-09-29 2007-07-12 Kissei Pharmaceutical Compuesto heterociclico nitrogenoso 1-(b-d-glicopiranosil)-3, composicion medicinal que contiene el mismo, y uso medicinal del mismo.
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200635599A (en) * 2004-12-16 2006-10-16 Boehringer Ingelheim Int Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
UA90290C2 (ru) * 2005-01-28 2010-04-26 Чугаи Сейяку Кабусики Кайся Производные спирокеталов и их применение в качестве лекарственного средства против диабета
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
JP4496174B2 (ja) * 2005-01-31 2010-07-07 田辺三菱製薬株式会社 医薬組成物
MY147375A (en) 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
AR053329A1 (es) 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
WO2006086464A2 (en) * 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
EP1856082B1 (en) 2005-02-23 2009-10-14 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
WO2006099245A1 (en) * 2005-03-11 2006-09-21 Elixir Pharmaceuticals, Inc. Sirt inhibitors that bind to nad
WO2006113261A2 (en) 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
CA2605245A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
US7723309B2 (en) * 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
US7772191B2 (en) * 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en) * 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
CA2614664A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obesity,metabolic syndrome and polycystic ovary syndrome
AR054871A1 (es) * 2005-07-27 2007-07-25 Boehringer Ingelheim Int Derivados de (hetero)cicloalquiletinil-bencil)-benceno sustituidos con glucopiranosilo, medicamentos que contienen dichos compuestos, sus uso y proceso para su fabricacion
WO2007016353A2 (en) * 2005-07-28 2007-02-08 Bristol-Myers Squibb Company Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
EP1924571B1 (en) * 2005-08-30 2010-10-13 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
NZ566787A (en) 2005-09-08 2010-02-26 Boehringer Ingelheim Int Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
JP2009531291A (ja) 2006-02-15 2009-09-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゾニトリル誘導体、それらの化合物を含有する医薬組成物、それらの使用及び製造方法
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
MX2008014512A (es) 2006-05-19 2008-11-27 Taisho Pharma Co Ltd Compuesto de c-fenil glucitol para el tratamiento de diabetes.
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
KR20090023570A (ko) * 2006-06-29 2009-03-05 다이쇼 세이야꾸 가부시끼가이샤 Ｃ-페닐 1-티오글루시톨 화합물
EP2046753A2 (en) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
CA2656847A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2008034859A1 (en) * 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
MX2009003927A (es) 2006-10-13 2009-04-23 Chugai Pharmaceutical Co Ltd Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
JP2010507629A (ja) 2006-10-27 2010-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−（β−Ｄ−グルコピラノス−１−イル）−１−メチル−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）−ベンジル］−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
ES2397664T3 (es) 2006-12-04 2013-03-08 Janssen Pharmaceutica, N.V. Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
EP2325182A1 (en) 2006-12-06 2011-05-25 Glaxosmithkline LLC Bicyclic compounds and use as antidiabetics
WO2008075736A1 (ja) 2006-12-21 2008-06-26 Astellas Pharma Inc. Ｃ－グリコシド誘導体の製造方法及びその合成中間体
US7795228B2 (en) * 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
CA2679310A1 (en) * 2007-02-21 2008-08-28 Boehringer Ingelheim International Gmbh Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
AR065913A1 (es) * 2007-04-02 2009-07-08 Theracos Inc Derivados de glicosido bencilico, composicion y combinacion farmaceutica y uso
EP2474549A1 (en) 2007-04-17 2012-07-11 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type I inhibitors
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
CN101754972A (zh) * 2007-05-18 2010-06-23 百时美施贵宝公司 Sglt2抑制剂的晶体结构及其制备方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8383609B2 (en) 2007-07-05 2013-02-26 Centre National De La Recherche Scientifique Phosphorus containing heterocyclic compounds, sugar analogues, and compositions having anti-cancer activity containing the same
CN101343296B (zh) * 2007-07-10 2013-04-10 莱西肯医药有限公司 钠-葡萄糖协同转运蛋白2的抑制剂及其用法
BRPI0813840A2 (pt) * 2007-07-26 2017-06-06 Lexicon Pharmaceuticals Inc métodos e compostos úteis para a preparação de inibidores de cotransportador 2 de glicose de sódio
CN101808995A (zh) * 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
EP2187742B1 (en) 2007-08-23 2017-10-25 Theracos Sub, LLC (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol derivatives for use in the treatment of diabetes
BRPI0816258B8 (pt) 2007-09-10 2022-12-27 Mitsubishi Tanabe Pharma Corp processo para a preparação de compostos úteis como inibidores de sglt
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN101503399B (zh) * 2008-02-04 2012-06-27 白鹭医药技术（上海）有限公司 C-芳基葡萄糖苷sglt2抑制剂
WO2009117367A1 (en) * 2008-03-18 2009-09-24 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof
FR2929615B1 (fr) 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
CA2725047A1 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
HRP20161648T1 (hr) 2008-08-22 2017-02-10 Theracos Sub, Llc Postupak za pripravu sglt2 inhibitora
WO2010023594A1 (en) * 2008-08-28 2010-03-04 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
RU2411936C2 (ru) * 2009-01-11 2011-02-20 Институт физиологии Коми научного центра Уральского отделения Российской академии наук. Государственное учреждение Применение 2-морфолино-5-фенил-6н-1,3,4-тиадизин, гидробромида в качестве средства, обладающего гиполипидемическим и гипергликемическим эффектом
ES2982194T3 (es) 2009-02-13 2024-10-15 Boehringer Ingelheim Int Composición farmacéutica que comprende derivados de glucopiranosilo, difenilmetano, forma de dosificación farmacéutica de la misma, proceso para su preparación y usos de la misma para el control glucémico mejorado en un paciente
UY32441A (es) 2009-02-13 2010-09-30 Boehringer Ingelheim Int Composicion farmaceutica, metodos de tratamiento y sus usos
EP2396005B1 (en) 2009-02-13 2025-11-26 Boehringer Ingelheim International GmbH SGLT2 inhibitor for improving glycemic control
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
WO2010104818A1 (en) 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
US8563583B2 (en) 2009-03-09 2013-10-22 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
JP2012528170A (ja) * 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2451797B1 (en) 2009-07-10 2013-04-03 Janssen Pharmaceutica, N.V. CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
WO2011039108A2 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
DK2483286T3 (en) 2009-09-30 2016-09-19 Boehringer Ingelheim Int PROCESS FOR THE PREPARATION OF A crystal form of 1-chloro-4- (BETA-D-glucopyranos-1-yl) -2- (4 - ((S) -tetrahydrofuran-3-yloxy) benzyl) benzene
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
LT2488515T (lt) 2009-10-14 2017-03-10 Janssen Pharmaceutica Nv Junginių, naudotinų kaip sglt2 inhibitorių, paruošimo būdas
KR20120087950A (ko) 2009-10-20 2012-08-07 노파르티스 아게 글리코시드 유도체 및 그의 용도
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
PL2496583T3 (pl) 2009-11-02 2015-04-30 Pfizer Pochodne dioksabicyklo[3.2.1]oktano-2,3,4-triolowe
TR201816242T4 (tr) 2009-11-13 2018-11-21 Astrazeneca Ab Çabuk salımlı tablet formülasyonları.
WO2011070592A2 (en) * 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011120923A1 (en) 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
US8592396B2 (en) 2010-04-14 2013-11-26 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
PT2568988T (pt) 2010-05-11 2016-09-22 Janssen Pharmaceutica Nv Formulações farmacêuticas compreendendo derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenzeno como inhibidoras de sglt
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
US20130224296A1 (en) 2010-09-03 2013-08-29 Bristol-Myers Squibb Company Drug Formulations Using Water Soluble Antioxidants
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
JP2014504639A (ja) 2011-02-01 2014-02-24 ブリストル−マイヤーズ スクイブ カンパニー アミン化合物を含む医薬製剤
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6105489B2 (ja) 2011-02-18 2017-03-29 シャンハイ インリ ファーマシューティカル カンパニー リミティド アリールグルコシド化合物、その調製方法及び使用
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CN102675378A (zh) * 2011-03-09 2012-09-19 天津药物研究院 一类含环丙烷结构的c-葡萄糖苷衍生物、其制备方法和用途
US9346852B2 (en) 2011-03-14 2016-05-24 Bristol-Myers Scuibb Company Substituted adipic acid amides and uses thereof
US10544135B2 (en) 2011-04-13 2020-01-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
CN103619862A (zh) 2011-04-14 2014-03-05 诺瓦提斯公司 糖苷衍生物及其用途
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US9034921B2 (en) * 2011-06-01 2015-05-19 Green Cross Corporation Diphenylmethane derivatives as SGLT2 inhibitors
KR20140030231A (ko) 2011-06-03 2014-03-11 베링거 인겔하임 인터내셔날 게엠베하 신경이완제로 치료받는 환자에서 대사 장애를 치료하기 위한 ｓｇｌｔ－２ 억제제
EP2717689A4 (en) * 2011-06-13 2014-11-05 Panacea Biotec Ltd NEW SGLT HEMMER
CN102827122B (zh) * 2011-06-17 2015-01-14 山东轩竹医药科技有限公司 糖苷衍生物
WO2013000275A1 (zh) * 2011-06-25 2013-01-03 山东轩竹医药科技有限公司 C-糖苷衍生物
US20130035298A1 (en) 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8710049B2 (en) 2011-07-18 2014-04-29 Bristol-Myers Squibb Company Diaminocyclohexane compounds and uses thereof
US8815909B2 (en) 2011-07-18 2014-08-26 Bristol-Myers Squibb Company Diaminocyclohexane compounds and uses thereof
JP2014530186A (ja) 2011-09-13 2014-11-17 パナセア バイオテック リミテッド 新規ｓｇｌｔ阻害剤
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
WO2013178064A1 (zh) * 2012-05-29 2013-12-05 广东东阳光药业有限公司 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
RU2015110979A (ru) 2012-08-30 2016-10-20 Тайсо Фармасьютикал Ко., Лтд. Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
CN103910769B (zh) 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
EP3466431B1 (en) 2013-03-14 2023-11-15 MSD International GmbH Crystalline forms and methods for preparing sglt2 inhibitors
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
CN104059042B (zh) * 2013-03-22 2017-02-08 正大天晴药业集团股份有限公司 C-三芳基葡萄糖苷类sglt-2抑制剂
DK2981269T3 (da) 2013-04-04 2023-10-23 Boehringer Ingelheim Vetmedica Gmbh Behandling af stofskifteforstyrrelser hos hestedyr
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
CA3175715A1 (en) 2013-04-18 2014-10-23 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
CN107311992B (zh) * 2013-09-09 2020-08-18 上海研健新药研发有限公司 C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用
EP2895490B1 (en) 2013-09-27 2016-10-19 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
EP4285995A3 (en) 2013-12-17 2024-02-28 Boehringer Ingelheim Vetmedica GmbH An sglt-2 inhibitor for use in the treatment of a metabolic disorder in feline animals
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
EP2891654B1 (en) 2014-01-03 2016-06-22 Xuanzhu Pharma Co., Ltd. Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)
US9315438B2 (en) 2014-01-03 2016-04-19 Xuanzhu Pharma Co., Ltd Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
ES2712860T3 (es) * 2014-01-23 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabólicos en animales caninos
EP3114115A4 (en) * 2014-03-06 2017-08-23 MSN Laboratories Private Limited Process for the preparation of (1s)-1,5-anhydro-1-c-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-d-glucitol and its solvate thereof
DK3125882T3 (da) 2014-04-01 2020-06-29 Boehringer Ingelheim Vetmedica Gmbh Behandling af metabolske lidelser i hestedyr
CN105001213B (zh) * 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
TW201623321A (zh) 2014-05-13 2016-07-01 韓美藥品股份有限公司 雙環衍生物及包含其之藥學組成物
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
CN105085494B (zh) * 2014-05-22 2019-07-02 中国医学科学院药物研究所 钠糖共转运体2抑制剂、其制法和其药物组合物与用途
EP3197555A1 (en) 2014-09-25 2017-08-02 AstraZeneca Aktiebolag Combination of an omega-3 fatty acid and an sglt-2 inhibitor for treating diseases of the liver
CA2956257C (en) 2014-09-25 2022-07-12 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
CN104327027B (zh) * 2014-10-14 2017-04-05 中国药科大学 一类新型c‑芳基葡萄糖苷sglt2抑制剂
EP3256482B1 (en) * 2015-02-09 2019-11-27 Indoco Remedies Limited Process for the preparation of sglt inhibitor compounds
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2016161995A1 (en) 2015-04-08 2016-10-13 Zentiva, K.S. Solid forms of amorphous dapagliflozin
CN106317068A (zh) * 2015-06-23 2017-01-11 中国科学院上海药物研究所 一种c,o-螺环芳基糖苷类化合物及其制备和应用
MX389367B (es) 2015-08-27 2025-03-20 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2.
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
WO2017064193A1 (en) 2015-10-15 2017-04-20 Boehringer Ingelheim International Gmbh Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
WO2017099496A1 (ko) 2015-12-11 2017-06-15 동아에스티 주식회사 다파글리플로진의 신규 용매화물 및 이의 제조방법
CN106892929B (zh) * 2015-12-17 2020-01-14 上海艾力斯医药科技有限公司 螺缩酮衍生物及其制备方法和应用
CN105693669A (zh) * 2015-12-28 2016-06-22 南昌大学 一种抗糖尿病化合物及其制备方法和用途
EP3404033B1 (en) * 2016-01-04 2020-08-05 Jeil Pharmaceutical Co., Ltd. C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same
WO2017141202A1 (en) 2016-02-17 2017-08-24 Lupin Limited Complex of sglt2 inhibitor and process for preparation thereof
US9834533B2 (en) * 2016-02-19 2017-12-05 Scinopharm Taiwan, Ltd. Process for preparing SGLT2 inhibitors and intermediates thereof
WO2017221211A1 (en) * 2016-06-24 2017-12-28 Biocon Limited Process for the preparation of dapagliflozin and its solvate thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2018073154A1 (en) 2016-10-19 2018-04-26 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
KR20250097990A (ko) 2016-11-10 2025-06-30 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
US11020412B2 (en) 2017-03-16 2021-06-01 Inventia Healthcare Limited Pharmaceutical composition comprising dapagliflozin
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
EP3781166A1 (en) 2018-04-17 2021-02-24 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
KR102204439B1 (ko) 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
KR20200022257A (ko) * 2018-08-22 2020-03-03 동아에스티 주식회사 Sglt-2 억제제인 다파글리플로진 전구체의 제조방법
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
AU2019373306B2 (en) 2018-10-29 2024-10-10 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN111471032B (zh) * 2019-01-24 2023-08-01 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物的合成方法及其中间体和应用
WO2020151621A1 (zh) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 化合物、其制备方法及医药用途
CN111471031B (zh) * 2019-01-24 2023-05-16 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物及其制备方法和应用
CN111471040B (zh) * 2019-01-24 2023-06-02 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物的合成方法及其中间体和应用
CN111840271B (zh) * 2019-04-25 2024-05-14 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物新用途
BR112020008705A2 (pt) 2019-08-30 2022-03-22 Astrazeneca Ab Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina
AU2020394498A1 (en) 2019-11-28 2022-06-09 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors in the drying-off of non-human mammals
CN119823184A (zh) 2020-02-07 2025-04-15 加舒布鲁姆生物公司 杂环glp-1激动剂
JP2021127332A (ja) * 2020-02-17 2021-09-02 株式会社トクヤマ ５−ブロモ−２−アルキル安息香酸の製造方法
KR20220143732A (ko) 2020-02-17 2022-10-25 베링거잉겔하임베트메디카게엠베하 고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
WO2021176096A1 (en) 2020-03-05 2021-09-10 Krka, D.D., Novo Mesto Pharmaceutical composition comprising sglt2 inhibitor
CN115209894B (zh) 2020-03-06 2025-05-02 弗特克斯药品有限公司 治疗apol-1依赖性局灶节段性肾小球硬化的方法
CN115916197A (zh) 2020-04-22 2023-04-04 拜耳公司 用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合
WO2021219691A1 (en) 2020-04-29 2021-11-04 Astrazeneca Ab Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
WO2021245253A1 (en) 2020-06-05 2021-12-09 Krka, D.D., Novo Mesto Preparation of highly pure amorphous dapagliflozin
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
CN116323599A (zh) 2020-08-06 2023-06-23 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2022051316A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
JP2023551441A (ja) * 2020-11-19 2023-12-08 ベイジン・インクリーズ・イノベーティブ・ドラッグ・カンパニー，リミテッド グリコシド系誘導体及びその製造方法と応用
KR20220091233A (ko) 2020-12-23 2022-06-30 (주)국전약품 다파글리플로진 전구약물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
EP4315350A1 (en) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
JP2024527434A (ja) 2021-07-28 2024-07-24 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコ科動物を除く非ヒト哺乳動物、特にイヌ科動物における心臓疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
CA3224673A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
EP4490155A1 (en) 2022-03-09 2025-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250206757A1 (en) 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2023227492A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
WO2024033288A1 (en) * 2022-08-12 2024-02-15 Société des Produits Nestlé S.A. Salicin derivatives as inhibitors of sglt2
AR132054A1 (es) 2023-03-06 2025-05-21 Boehringer Ingelheim Vetmedica Gmbh Sistemas y métodos para la administración de composiciones farmacéuticas líquidas, en particular que comprenden uno o más inhibidores de sglt-2
TW202508593A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
TW202525278A (zh) 2023-12-15 2025-07-01 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 治療慢性腎病及高血壓之方法
WO2025224069A1 (en) 2024-04-23 2025-10-30 Bayer Aktiengesellschaft Co-crystals of finerenone, pecavaptan, and sglt2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5444050A (en) 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
JP2814950B2 (ja) 1994-05-11 1998-10-27 田辺製薬株式会社 血糖降下剤
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
FI974618A7 (fi) 1995-06-29 1997-12-23 Texas Biotechnology Corp Kahden- ja kolmenarvoiset pienimolekyyliset selektiininestäjät
JP3065235B2 (ja) 1995-11-07 2000-07-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3006513B2 (ja) 1995-11-07 2000-02-07 田辺製薬株式会社 医薬組成物
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3034192B2 (ja) 1995-11-07 2000-04-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
TW406086B (en) 1996-12-26 2000-09-21 Tanabe Seiyaku Co Propiophenone derivatives and process for preparing the same
WO1998031697A1 (en) * 1997-01-15 1998-07-23 Sankyo Company, Limited Aryl c-glycoside compounds and sulfated esters thereof
JPH10245391A (ja) 1997-03-03 1998-09-14 Dainippon Ink & Chem Inc ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
US6486299B1 (en) * 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
US6069238A (en) 1998-09-30 2000-05-30 Eli Lilly And Company Spirocyclic C-glycosides
DE60009929T2 (de) * 1999-08-31 2005-03-31 Kissei Pharmaceutical Co., Ltd., Matsumoto Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung

Also Published As

Publication number Publication date
US6414126B1 (en) 2002-07-02
PT1224195E (pt) 2005-07-29
BRPI0014722B8 (pt) 2021-05-25
CZ20021285A3 (cs) 2003-02-12
BRPI0014722B1 (pt) 2019-09-24
EP1224195B1 (en) 2005-05-18
MY125405A (en) 2006-07-31
HU229446B1 (en) 2013-12-30
HUP0300393A2 (hu) 2003-06-28
AU781009B2 (en) 2005-04-28
BR0014722A (pt) 2003-02-25
WO2001027128A1 (en) 2001-04-19
DE60020259D1 (de) 2005-06-23
TWI254714B (en) 2006-05-11
CA2388818C (en) 2012-07-03
HK1044541A1 (en) 2002-10-25
TR200200986T2 (tr) 2002-07-22
CN1407990A (zh) 2003-04-02
CA2388818A1 (en) 2001-04-19
AU7848300A (en) 2001-04-23
IL148806A (en) 2010-06-16
JP4365554B2 (ja) 2009-11-18
NO332798B1 (no) 2013-01-14
DE60020259T2 (de) 2006-01-19
MXPA02003625A (es) 2002-10-23
HUP0300393A3 (en) 2003-09-29
NZ518029A (en) 2004-08-27
PH12000002657B1 (en) 2006-02-21
CZ304522B6 (cs) 2014-06-18
ES2240179T3 (es) 2005-10-16
PL204358B1 (pl) 2010-01-29
IL148806A0 (en) 2002-09-12
NO323698B1 (no) 2007-06-25
UY26391A1 (es) 2001-05-31
EG24515A (en) 2009-08-19
CO5251414A1 (es) 2003-02-28
EP1224195A1 (en) 2002-07-24
JP2003511458A (ja) 2003-03-25
NO20021721D0 (no) 2002-04-11
PE20011000A1 (es) 2001-11-25
HU230727B1 (hu) 2017-12-28
HK1044541B (en) 2005-11-11
IN2007MU00019A (forum.php) 2007-08-03
RU2262507C2 (ru) 2005-10-20
PL355018A1 (en) 2004-03-22
KR100728085B1 (ko) 2007-06-14
NO20070149L (no) 2002-06-10
KR20020063876A (ko) 2002-08-05
CN1284793C (zh) 2006-11-15
NO20021721L (no) 2002-06-10
ATE295848T1 (de) 2005-06-15
MX237254B (es) 2006-05-26
RU2002109477A (ru) 2004-01-20

Similar Documents

Publication Publication Date Title
AR026024A1 (es) Compuestos inhibidores sglt2 de glucosidos de c-arilo y metodo, las composiciones faramceuticas que los contienen y los intermediarios de sintesis dedichos compuestos
NO2022019I1 (no) Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC
CY1105038T1 (el) Συμπλοκα αμινοξεων απο c-αρυλγλυκοζιτες για την θεραπευτικη αγωγη του διαβητη και μεθοδος
ES2195034T3 (es) Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion.
KR950701317A (ko) 인돌 유도체(Indole Derivative)
ES8603455A1 (es) Un metodo para preparar derivados de piperazina
ES2172580T3 (es) 1,3-oxatiolanos sustituidos con propiedades antiviricas.
DE60324155D1 (de) Indol-3-carbinol metaboliten als chemotherapeutische und chemopräventive wirkstoffen
AR015449A1 (es) Derivados piperidil- o peperazinil-dihidro sustituidos-2h-1-benzopirano composicion farmaceutica que los contiene, su uso para la elaboracion de unmedicamento, procedimiento para su preparacion y compuesto intermediario para su exclusivo uso en dicho procedimiento
DK229187A (da) 1-substituerede imidazolderivater, 2-thion-tautomere og ikke-toksiske, farmaceutisk acceptable salte deraf
ES2038074B1 (es) Procedimiento para la preparacion de nuevos derivados de benzimidazol.
ES2069536T3 (es) Analogos del activador del plasminogeno tisular que tienen dominios modificados del factor de crecimiento.
AR002741A1 (es) Benciloxicarbonilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico asi como medicamentoque las contiene
PE107599A1 (es) Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h)-tiofenonas como agentes antitumorales
DE59002760D1 (de) K2p pro-stabilisierung.
DE3785393D1 (de) 4-(aroylamino)piperidinbutanamide derivate.
DK601583D0 (da) Carbamyloxybenzhydrolderivater
SE8802066D0 (sv) N-imidazolyl derivatives of bicyclic compounds useful in medicine
DK185984D0 (da) Disubstituerede polymethyleniminer,fremgangsmaader til deres fremstilling og farmaceutiske kompositioner indeholdende dem
UY28618A1 (es) Nuevos indoles sustituidos de piperidina o heteroderivados de los mismos
WO2001038316A3 (de) Sulfonyloxazolamine und deren verwendung als 5-ht6 rezeptorliganden
MX9204220A (es) Bencimidazoles.
PE20040582A1 (es) Inhibidores de vasopeptidasa
PE20040723A1 (es) Derivados benzofurano y benzotiofeno

Legal Events

Date Code Title Description
FG Grant, registration